Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Royalty PharmaFRA:RPD -1.08%69 3-Year EBITDA Growth Rate is 44.20% as of Jun. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 69/100 and a GF Value™ of €33.09 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,132 Biotechnology companies, Royalty Pharma ranks better than 80.92% on this metric.
During the past 12 months, Royalty Pharma's average EBITDA Per Share Growth Rate was -10.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -6.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Royalty Pharma was 44.20% per year. The lowest was -50.10% per year. And the median was -10.65% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Royalty Pharma 3-Year EBITDA Growth Rate Related Terms
FRA:RPD vs ROIV, INCY, INSM: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Royalty Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.20% mean?
Royalty Pharma (FRA:RPD) has a 3-Year EBITDA Growth Rate of 44.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #216 out of 1132 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Royalty Pharma's 3-Year EBITDA Growth Rate too high?
Royalty Pharma's current 3-Year EBITDA Growth Rate is 44.20%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Royalty Pharma's value of 44.20% is 197.6% above this industry median. Based on the distribution chart, Royalty Pharma ranks #216 out of 1132 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's 3-Year EBITDA Growth Rate compare to ROIV and INCY?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #216 out of 1132 companies for 3-Year EBITDA Growth Rate. This places Royalty Pharma in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Royalty Pharma's value of 44.20% is 197.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,132 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Royalty Pharma's current 3-Year EBITDA Growth Rate of 44.20% is 197.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Royalty Pharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current 3-Year EBITDA Growth Rate is 44.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €33.09, compared to a current price of €48.55 — trading 46.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 44.20% and 197.6% above the Biotechnology industry median of 14.85. Royalty Pharma's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current 3-Year EBITDA Growth Rate is 44.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (FRA:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €48.55 is trading 46.7% above its estimated GF Value™ of €33.09.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for FRA:RPD:
3-Year EBITDA Growth Rate: 44.20%
GF Value™: €33.09 vs. price of €48.55 (46.7% above fair value)
Industry Position: 197.6% above the Biotechnology median (#216 of 1132)
No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
69GF Score
Get the complete analysis for FRA:RPD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RPD has been successfully added to your 
